Fidelity International
BBIO icon

Fidelity International’s BridgeBio Pharma BBIO Stock Holding History

Fidelity International’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.54K Buy
+88
New +$6.38K ﹤0.01% 1095
2019
Q3 		– Sell
-289,448
Closed -$7.81M – 894
2019
Q2 		$7.81M Buy
+289,448
New +$7.89M 0.01% 495

Other funds holding BBIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity International's BBIO Position: Q1 2026 in Review

Fidelity International opened a new position in BridgeBio Pharma (BBIO) in Q1 2026: 88 shares worth $6.54K. The stake represents ﹤0.01% of the portfolio and ranks #1095 among its holdings. This is a return to the name: Fidelity International previously reported a position in BBIO as recently as Q2 2019.

Fidelity International first reported a position in BBIO in Q2 2019 and has held it in 2 quarters since. The position peaked at $7.81M in Q2 2019. 458 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

  • Fidelity International held 88 shares of BridgeBio Pharma worth $6.54K as of Q1 2026.
  • BridgeBio Pharma was a new Fidelity International position in Q1 2026.
  • BridgeBio Pharma made up ﹤0.01% of Fidelity International's portfolio in Q1 2026, its #1095 holding.
  • Fidelity International first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 2 quarters since.
  • Fidelity International's BridgeBio Pharma position peaked at $7.81M in Q2 2019.
  • 458 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Fidelity International's 13F filing for Q1 2026, filed 15 May 2026.